Literature DB >> 7739765

Differences in effects of sultopride and sulpiride on dopamine turnover in rat brain.

K Moriuchi1, Y Imazu, H Yoneda.   

Abstract

Sultopride and sulpiride are both chemically similar benzamide derivatives and selective antagonists of dopamine D2 receptors. However, these drugs differ in clinical properties. We compared the effects of sultopride and sulpiride on dopamine turnover in rats following the administration of these drugs alone or in combination with apomorphine. The administration of sultopride or sulpiride markedly accelerated dopamine turnover in the rat brain. The increase in the level of dopamine metabolites in the striatum was more marked in the sultopride-treated rats. Sulpiride affected the limbic dopamine receptors preferentially, whereas sultopride affected the striatal and the limbic dopamine receptors equally. A low dose of apomorphine induced a reduction in the concentration of dopamine metabolites in the striatum and the nucleus accumbens by approximately 55%, but not in the medial prefrontal cortex. Sultopride was more effective in preventing an apomorphine-induced reduction in dopamine metabolite levels. These results from rat experiments would model the pharmacological differences observed between sultopride and sulpiride in clinical use.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7739765     DOI: 10.1007/bf00995158

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  22 in total

1.  Limbic selective neuroleptics.

Authors:  S Bischoff
Journal:  Clin Neuropharmacol       Date:  1992       Impact factor: 1.592

2.  [Therapeutic method derived from hiberno-therapy in excitation and agitation states].

Authors:  J DELAY; P DENIKER; J M HARL
Journal:  Ann Med Psychol (Paris)       Date:  1952-07       Impact factor: 0.380

Review 3.  Multiple receptors for dopamine.

Authors:  J W Kebabian; D B Calne
Journal:  Nature       Date:  1979-01-11       Impact factor: 49.962

4.  Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics.

Authors:  P Sokoloff; B Giros; M P Martres; M L Bouthenet; J C Schwartz
Journal:  Nature       Date:  1990-09-13       Impact factor: 49.962

5.  A comparison of in vitro and in vivo dopamine receptor antagonism produced by substituted benzamide drugs.

Authors:  P Jenner; P N Elliott; A Clow; C Reavill; C D Marsden
Journal:  J Pharm Pharmacol       Date:  1978-01       Impact factor: 3.765

6.  Alternative splicing directs the expression of two D2 dopamine receptor isoforms.

Authors:  B Giros; P Sokoloff; M P Martres; J F Riou; L J Emorine; J C Schwartz
Journal:  Nature       Date:  1989 Dec 21-28       Impact factor: 49.962

7.  Regional distribution of sultopride and sulpiride in rat brain measured by radioimmunoassay.

Authors:  A Mizuchi; N Kitagawa; Y Miyachi
Journal:  Psychopharmacology (Berl)       Date:  1983       Impact factor: 4.530

8.  Mesocortical dopamine neurons. Lack of autoreceptors modulating dopamine synthesis.

Authors:  M J Bannon; R L Michaud; R H Roth
Journal:  Mol Pharmacol       Date:  1981-03       Impact factor: 4.436

9.  Controlled trial of sulpiride in chronic schizophrenic patients.

Authors:  J G Edwards; J R Alexander; M S Alexander; A Gordon; T Zutchi
Journal:  Br J Psychiatry       Date:  1980-12       Impact factor: 9.319

10.  Rapid concurrent automated fluorimetric assay of noradrenaline, dopamine, 3,4-dihydroxyphenylacetic acid, homovanillic acid and 3-methoxytyramine in milligram amounts of nervous tissue after isolation on Sephadex G10.

Authors:  B H Westerink; J Korf
Journal:  J Neurochem       Date:  1977-10       Impact factor: 5.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.